Jubilant Life Sciences

Noida, India Founded: 1978 • Age: 48 yrs Listed
Company offering a suite of RD and manufacturing services for small molecules and generics
Request Access
Report Incorrect Data
Page last updated

About Jubilant Life Sciences

Jubilant Life Sciences is a publicly listed company based in Noida (India) founded in 1978 by Hari Bhartia. Company offering a suite of RD and manufacturing services for small molecules and generics. The company has 165 employees. Jubilant Life Sciences has completed 5 acquisitions, including Bestcro, DRAXIS Health and Hollister-Stier. Its website jubl.com draws about 48 thousand monthly visits. Its Indian entity Jubilant Pharmova Limited reported revenue of ₹8,346 Cr. Jubilant Life Sciences offers products and services including Pharmaceuticals, Drug Discovery Solutions, Proprietary Novel Drugs, and Specialty Chemicals. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Formulation. Its competitors include Akums, Nectar Lifesciences and Windlas; 3 of its 3 listed competitors have raised funding.

Company details

Founded in 1978, operations are conducted in the pharmaceutical and life sciences sectors from Noida, India. APIs, solid dosage formulations, radiopharmaceuticals, and allergy therapy products are manufactured and supplied, alongside contract services for sterile injectables and drug discovery. Advanced intermediates, fine ingredients, and nutritional products are also produced. Facilities are maintained in India and North America, with products distributed to over 100 countries across North America, Europe, India, and China.

Operational Areas
Healthcare → Biopharma Outsourcing & Drug Delivery
Key Metrics
  • Market Cap
    ₹15,388 Cr

    JUBLPHARMA · NSE

  • Share Price
    ₹966.00

    +2.44% today

  • Revenue
    ₹8,280 Cr

    FY 2025-26 · +14.5% YoY

  • EBITDA
    ₹1,200 Cr

    Margin 14.5%

  • Net Profit
    ₹436 Cr

    FY 2025-26 · +9.1% YoY

  • P/E (TTM)
    38.6x

    P/B 2.1x

  • ROE
    6.0%

    ROCE 6.9%

  • Debt / Equity
    0.48

    Interest cover 27.9x

  • Latest Funding Round
    $86.11M (USD), Post-IPO

    Mar 2010

  • Investors
    General Atlantic
  • Employee Count
    165
  • Investments & Acquisitions
    Bestcro

    & 4 more

Products & Services of Jubilant Life Sciences

Jubilant Life Sciences offers a comprehensive portfolio of products and services, including Pharmaceuticals, Drug Discovery Solutions, Proprietary Novel Drugs, and Specialty Chemicals.

Pharmaceuticals
Health Products

Products for addressing unmet health needs through research and manufacturing.

Drug Discovery Solutions
Research Services

Services focused on developing innovative drug solutions for global markets.

Proprietary Novel Drugs
Innovation Products

Specialized drugs created to meet specific health challenges affordably.

Specialty Chemicals
Life Science Ingredients

Chemicals for nutrition and health applications in various industries.

Funding Insights of Jubilant Life Sciences

  • Total Rounds 3
  • Last Round Post-IPO — $86.11M
  • First Round $1.5M

    (Jun 2003)

  • Investors Count 1

All 3 funding rounds of Jubilant Life Sciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Mar 2010$86.11MPost-IPO––
–
Jun 2005Post-IPO––
General Atlantic
Jun 2003$1.5MDebt – Conventional––
–
Valuation history

1 investors in total: 1 institutional.

Investors in Jubilant Life Sciences

Jubilant Life Sciences has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include General Atlantic.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
General Atlantic
Private equity fund focused on global markets
1980generalatlantic.comNew York, United States
Premium access

Investor details for Jubilant Life Sciences

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Jubilant Pharmova Limited (Jubilant Life Sciences)

Jubilant Pharmova Limited is the primary company behind Jubilant Life Sciences. The boards of the 4 registered companies of Jubilant Life Sciences currently have 18 directors; the longest-serving is Shyam Sunder Bhartia, appointed in 1978. 80 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Shyam Sunder Bhartia
DIN 00010484
Director21 Jun 197848 yrs 4 moJubilant Pharmova Limited
Hari Shanker Bhartia
DIN 00010499
Director01 Nov 198343 yrsJubilant Pharmova Limited
Sankaraiah Rajagopal
DIN 00025022
Director29 Nov 200718 yrs 11 moJubilant Innovation (India) Limited
Sanjay Gupta
DIN 00095510
Director24 Mar 201511 yrs 7 moJubilant First Trust Healthcare Limited
Benny Thomas
DIN 07241561
Director29 Jan 201610 yrs 9 moJubilant Innovation (India) Limited, Vanthys Pharmaceutical Development Private Limited
Priyavrat Bhartia
DIN 00020603
Managing Director23 May 20179 yrs 5 moJubilant Pharmova Limited
Arjun Shanker Bhartia
DIN 03019690
Managing Director23 May 20179 yrs 5 moJubilant Pharmova Limited
Vivek Mehra
DIN 00101328
Director23 May 20179 yrs 5 moJubilant Pharmova Limited
Sushil Kumar Roongta
DIN 00309302
Director23 May 20179 yrs 5 moJubilant Pharmova Limited
Shwetank Tiwari
DIN 02413671
Company Secretary16 Jan 20188 yrs 9 moVanthys Pharmaceutical Development Private Limited
Shyamsundar Bang
DIN 00011327
Director28 Mar 20188 yrs 7 moVanthys Pharmaceutical Development Private Limited
Arun Seth
DIN 00204434
Director22 Oct 20188 yrsJubilant Pharmova Limited
Arun Kumar Sharma
DIN 06991435
Additional Director29 Apr 20197 yrs 6 moJubilant Innovation (India) Limited, Jubilant First Trust Healthcare Limited
Saravanakumar Dhakshinamoorthy
DIN 08448999
Additional Director15 May 20197 yrs 5 moVanthys Pharmaceutical Development Private Limited
Devarajan Jagannathan
DIN 09244642
Director01 Dec 20223 yrs 11 moJubilant First Trust Healthcare Limited
Shirish Gundopant Belapure
DIN 02219458
Director07 Mar 20233 yrs 8 moJubilant Pharmova Limited
Shivpriya Nanda
DIN 01313356
Director01 Apr 20242 yrs 7 moJubilant Pharmova Limited
Harsh Mahajan
DIN 00824227
Director01 Apr 20242 yrs 7 moJubilant Pharmova Limited

People of Jubilant Life Sciences

1 people are tracked at Jubilant Life Sciences (1 in leadership); the tracked headcount is 165.

NameRoleGroup
Hari Bhartia
Co-FounderLeadership
Premium access

Complete people profiles for Jubilant Life Sciences

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Jubilant Life Sciences

Jubilant Life Sciences is a publicly listed company on the NSE with ticker symbol JUBLPHARMA in India, operating in the Pharmaceuticals sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date16 Jun 2003
  • Listed onNSE: JUBILANT
  • Listed entityJubilant Pharmova Limited
  • Exchange sectorPharmaceuticals

Financials of Jubilant Life Sciences

Exchange-reported figures of Jubilant Pharmova Limited, the listed company behind Jubilant Life Sciences (NSE: JUBLPHARMA).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹8,280 Cr
+14.4% YoY
EBITDA
₹1,200 Cr
+2.3% YoY
Profit After Tax
₹436 Cr
+9.1% YoY
Net Worth
₹7,093 Cr
+13.4% YoY
Total Assets
₹13,048 Cr
+21.2% YoY
Total Debt
₹3,615 Cr
+32.4% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue8,2807,2346,7036,2826,1306,0995,976
Revenue growth+14.5%+7.9%+6.7%+2.5%+0.5%+2.1%-
EBITDA1,2001,1737327191,1461,3751,515
EBITDA margin+14.5%+16.2%+10.9%+11.5%+18.7%+22.6%+25.4%
Profit before tax61498117027.806301,1331,233
Net profit43640045.30(389)416856922
Net profit margin+5.3%+5.5%+0.7%-6.2%+6.8%+14.0%+15.4%
EPS (₹)25.2253.134.88(3.84)26.0052.5156.39
Balance sheet
Total assets13,04810,7629,7489,4318,6127,69210,572
Net worth7,0936,2555,4345,3995,3194,7415,604
Total debt3,6152,7313,6643,6773,1922,8304,808
Cash & bank1,2681,0899571,0149846711,400
Net working capital1,8851,7552,2862,3432,4331,9743,352
Cash flow
Cash from operations1,2271,0729716618381,7841,543
Cash from investing(1,143)512(596)(474)(323)(727)(267)
Cash from financing94.90(1,453)(432)(157)(32.60)(1,709)(1,050)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,2292,2902,1221,9661,9011,9291,8221,752
Revenue growth (YoY)+17.3%+18.7%+16.5%+12.2%+9.8%---
Other income19.9023.7020.509.8012.0011.909.2021.70
EBITDA248326250336290342268275
EBITDA margin+11.2%+14.3%+11.8%+17.1%+15.4%+17.9%+14.8%+15.8%
Depreciation12711712110598.1095.2091.3091.40
Interest54.2056.5056.1050.2049.0052.7055.6061.00
Profit before tax86.4017693.40190154206130144
Tax30.0056.7037.6070.4051.9054.7029.8041.90
Net profit56.4011955.80120102151101102
EPS (₹)3.567.523.527.576.479.686.366.46
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2642317858107262,7103,140
Revenue growth+13.9%-70.5%-3.1%+11.6%-73.2%-13.7%-
EBITDA40.1037.7016.503.106.46427369
EBITDA margin+15.2%+16.3%+2.1%+0.4%+0.9%+15.8%+11.8%
Profit before tax72.5038.4041.7079.3084.72273299
Net profit70.8422.2032.3649.6580.47215326
Net profit margin+26.9%+9.6%+4.1%+6.1%+11.1%+7.9%+10.4%
EPS (₹)3.971.211.993.145.0513.4620.16
Balance sheet
Total assets2,3772,6822,7822,7842,6461,7914,687
Net worth2,3122,3182,3742,4142,4391,2822,607
Total debt52.703363803461835042,013
Cash & bank10.3012.6036.1011.0022.5340.33258
Net working capital(4.60)25733135427622.01987
Cash flow
Cash from operations93.60136143(65.10)(3.55)608317
Cash from investing34.00(2.30)(40.30)31.1093.10178(198)
Cash from financing(130)(157)(77.80)22.50(107)(782)(41.05)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue67.1070.3067.3066.4059.5060.7056.1061.40
Revenue growth (YoY)+12.8%+15.8%+20.0%+8.1%+11.8%---
Other income0.100.500.4042.402.4013.002.8019.50
Total expenses55.1064.5055.1054.6049.2049.8046.1055.20
EBITDA12.005.8012.2011.8010.3010.9010.006.20
EBITDA margin+17.9%+8.3%+18.1%+17.8%+17.3%+18.0%+17.8%+10.1%
Depreciation1.401.301.601.601.501.501.501.70
Interest0.900.900.902.503.003.103.303.20
Profit before tax9.804.1010.1050.108.2019.308.0020.80
Tax2.50(53.10)3.5056.502.405.702.7010.30

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 10 Nov 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,2292,2902,1221,9661,9011,9291,8221,752
Revenue growth (YoY)+17.3%+18.7%+16.5%+12.2%+9.8%---
Other income19.9023.7020.509.8012.0011.909.2021.70
EBITDA248326250336290342268275
EBITDA margin+11.2%+14.3%+11.8%+17.1%+15.4%+17.9%+14.8%+15.8%
Depreciation12711712110598.1095.2091.3091.40
Interest54.2056.5056.1050.2049.0052.7055.6061.00
Profit before tax86.4017693.40190154206130144
Tax30.0056.7037.6070.4051.9054.7029.8041.90
Net profit56.4011955.80120102151101102
EPS (₹)3.567.523.527.576.479.686.366.46
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue8,2807,2346,7036,2826,1306,0995,976
Revenue growth+14.5%+7.9%+6.7%+2.5%+0.5%+2.1%-
Other income66.0041692.8050.6011.29291258
Total expenses7,0796,0615,9715,5624,9844,7234,461
Employee cost2,7012,2682,2162,1662,0431,9231,843
EBITDA1,2001,1737327191,1461,3751,515
EBITDA margin+14.5%+16.2%+10.9%+11.5%+18.7%+22.6%+25.4%
Depreciation440369382554382349340
Interest212240272188145184200
Profit before tax61498117027.806301,1331,233
Tax21714497.8092.70217297335
Net profit43640045.30(389)416856922
Net profit margin+5.3%+5.5%+0.7%-6.2%+6.8%+14.0%+15.4%
EPS (₹)25.2253.134.88(3.84)26.0052.5156.39
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital15.8015.8015.8015.9015.9215.9215.93
Reserves & surplus7,0776,2395,4185,3835,3034,7265,588
Shareholders' funds (net worth)7,0936,2555,4345,3995,3194,7415,604
Minority interest2.80(16.30)(12.80)(7.50)(2.16)0.030.00
Secured loans54045649652326540.78999
Unsecured loans3,0742,2753,1683,1532,9272,7893,810
Total debt3,6152,7313,6643,6773,1922,8304,808
Total liabilities13,04810,7629,7489,4318,6127,69210,572
Assets
Gross block10,1677,8237,8697,3686,6926,0907,983
Net block6,9665,1765,0915,1834,8714,6096,340
Capital work in progress4,0403,6302,1031,5621,090897768
Investments61.4043.5042.2025623924169.36
Inventories1,2321,1291,2901,3801,2551,1291,845
Sundry debtors1,0708929169619288201,293
Cash & bank balances1,2681,0899571,0149846711,400
Loans & advances541468714406342332500
Total current assets4,1093,5773,8763,7623,5092,9525,038
Total current liabilities2,2241,8221,5901,4191,0769791,686
Net working capital1,8851,7552,2862,3432,4331,9743,352
Total assets13,04810,7629,7489,4318,6127,69210,572
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash1,0889561,0149845021,1541,005
Net cash from operating activities1,2271,0729716618381,7841,543
Net cash from investing activities(1,143)512(596)(474)(323)(727)(267)
Net cash from financing activities94.90(1,453)(432)(157)(32.60)(1,709)(1,050)
Net change in cash179132(57.50)30.10482(652)225
Closing cash1,2681,0899571,0149846711,400
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+14.5%+7.9%+6.7%+2.5%+0.5%+2.1%-
EBITDA growth+2.3%+60.3%+1.7%-37.2%-16.6%-9.2%-
PBT growth-37.4%+475.1%+513.3%-95.6%-44.4%-8.2%+36.5%
Net income growth+9.1%+782.1%+111.6%-193.5%-51.4%-7.1%-
Revenue CAGR (3Y)+9.6%+5.7%+3.2%+1.7%-12.4%-6.7%+0.7%
EBITDA CAGR (3Y)+18.6%+0.8%-19.0%-22.0%-7.7%-3.3%+4.0%
Profitability & leverage
Net income margin+4.8%+11.6%+1.1%-1.0%+6.7%+13.7%+15.0%
Return on capital employed+6.9%+8.4%+6.4%+3.1%+9.5%+11.9%+14.1%
Return on net worth+6.0%+6.8%+0.8%-7.3%+8.2%+16.6%+17.3%
Debt / equity0.480.550.680.640.600.740.93
Long-term debt / equity0.430.490.620.560.540.640.78
Interest cover27.8729.8777.80113.7819.0317.9416.99
Efficiency & per share
Fixed asset turnover0.920.920.880.890.960.870.80
Inventory turnover7.015.985.024.775.144.103.66
Debtors turnover8.448.017.146.657.015.774.66
EPS (₹)25.2253.134.88(3.84)26.0052.5156.39
Dividend per share (₹)5.005.005.005.005.005.005.00
Book value per share (₹)448.91395.88343.92339.58334.10297.85351.78
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue67.1070.3067.3066.4059.5060.7056.1061.40
Revenue growth (YoY)+12.8%+15.8%+20.0%+8.1%+11.8%---
Other income0.100.500.4042.402.4013.002.8019.50
Total expenses55.1064.5055.1054.6049.2049.8046.1055.20
EBITDA12.005.8012.2011.8010.3010.9010.006.20
EBITDA margin+17.9%+8.3%+18.1%+17.8%+17.3%+18.0%+17.8%+10.1%
Depreciation1.401.301.601.601.501.501.501.70
Interest0.900.900.902.503.003.103.303.20
Profit before tax9.804.1010.1050.108.2019.308.0020.80
Tax2.50(53.10)3.5056.502.405.702.7010.30
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2642317858107262,7103,140
Revenue growth+13.9%-70.5%-3.1%+11.6%-73.2%-13.7%-
Other income45.7020.2010313812647.88173
Total expenses2231947688077192,2822,771
Employee cost10492.10190167164221265
EBITDA40.1037.7016.503.106.46427369
EBITDA margin+15.2%+16.3%+2.1%+0.4%+0.9%+15.8%+11.8%
Depreciation6.006.6048.3043.2036.9199.97107
Interest7.3012.9029.9018.5010.99102136
Profit before tax72.5038.4041.7079.3084.72273299
Tax9.3019.2010.1029.404.2358.69(22.30)
Net profit70.8422.2032.3649.6580.47215326
Net profit margin+26.9%+9.6%+4.1%+6.1%+11.1%+7.9%+10.4%
EPS (₹)3.971.211.993.145.0513.4620.16
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital15.9015.9015.9015.9015.9315.9315.93
Reserves & surplus2,2962,3022,3592,3992,4231,2672,591
Shareholders' funds (net worth)2,3122,3182,3742,4142,4391,2822,607
Secured loans50.0021326122295.0095.00899
Unsecured loans2.7012311912387.524091,114
Total debt52.703363803461835042,013
Total liabilities2,3772,6822,7822,7842,6461,7914,687
Assets
Gross block1561,0369979478631492,288
Net block1166997116876371271,865
Capital work in progress11.5019.3037.0047.0035.260.3359.09
Investments2,1761,6571,6571,6571,6461,6461,764
Inventories0.002322513143230.00656
Sundry debtors23.802061941881310.00425
Cash & bank balances10.3012.6036.1011.0022.5340.33258
Loans & advances16.8032.9059.4065.7049.4025.92383
Total current assets50.9048454157952666.251,722
Total current liabilities55.5022721022525044.24735
Net working capital(4.60)25733135427622.01987
Total assets2,3772,6822,7822,7842,6461,7914,687
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash12.6036.1011.0022.5040.3535.6418.70
Net cash from operating activities93.60136143(65.10)(3.55)608317
Net cash from investing activities34.00(2.30)(40.30)31.1093.10178(198)
Net cash from financing activities(130)(157)(77.80)22.50(107)(782)(41.05)
Net change in cash(2.30)(23.50)25.10(11.50)(17.82)4.6978.00
Closing cash10.3012.6036.1011.0022.5340.33258
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+13.9%-70.5%-3.1%+11.6%-73.2%-13.7%-
EBITDA growth+6.4%+128.5%+432.3%-52.0%-98.5%+15.7%-
PBT growth+88.8%-7.9%-47.4%-6.4%-69.0%-8.6%+62.9%
Net income growth+219.1%-31.4%-34.8%-38.3%-62.5%-34.2%-
Revenue CAGR (3Y)-31.2%-31.7%-33.8%-36.3%-40.5%-6.4%+8.0%
EBITDA CAGR (3Y)+134.7%+80.0%-66.2%-79.7%-72.8%-7.5%+5.1%
Profitability & leverage
Net income margin+24.0%+8.3%+4.0%+6.2%+11.1%+7.9%+10.2%
Return on capital employed+1.8%+1.9%+2.6%+3.6%+4.3%+11.6%+9.9%
Return on net worth+3.1%+0.8%+1.3%+2.1%+4.3%+11.0%+13.0%
Debt / equity0.080.150.150.110.180.650.75
Long-term debt / equity0.050.100.100.080.160.460.44
Interest cover21.4141.48-94.03-46.13-36.0931.1252.02
Efficiency & per share
Fixed asset turnover0.440.230.810.891.432.221.53
Inventory turnover2.270.962.782.544.498.265.47
Debtors turnover2.291.164.105.0811.1112.746.93
EPS (₹)3.971.211.993.145.0513.4620.16
Dividend per share (₹)5.005.005.005.005.005.005.00
Book value per share (₹)145.43145.79149.34151.86153.1180.51163.67

Investments & Acquisitions by Jubilant Life Sciences

Jubilant Life Sciences has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include Bestcro, DRAXIS Health and Hollister-Stier.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
DRAXIS Health
Radiopharmaceuticals are developed and manufactured for medical imaging applications.
draxis.comMississauga, Canada1995Apr 2008$255M
Hollister-Stier
Injectable CDMO services and allergy immunotherapy products are offered.
hollister-stier.comSpokane, United States1949Apr 2007$122.5M
Bestcro
Research consulting services are provided for pharmaceutical and biotech sectors.
bestcro.comChina1996Oct 2005$33.5M
Target Health
Full-service clinical research organization software and services are provided.
targethealth.comNew York, United States1993Oct 2005$33.5M
Target Research Group
Market research services are provided by Target Research Group.
targetresearchgroup.comNanuet, United States1986Jun 2005••••
Premium access

Complete acquisition details for Jubilant Life Sciences

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Jubilant Life Sciences

9 dated milestones of Jubilant Life Sciences across 32 years, from founding to its latest funding, stage changes and deals.

  1. Founded Jubilant Life Sciences is founded.
  2. Funding First funding round of $1.5M.
  3. IPO Lists on the stock exchange (IPO).
  4. Acquisition Acquires Target Research Group.
  5. Acquisition Acquires Bestcro.
  6. Acquisition Acquires Target Health.
  7. Acquisition Acquires Hollister-Stier.
  8. Acquisition Acquires DRAXIS Health.
  9. Funding Latest funding round, Post-IPO, of $86.1M.

Competitors of Jubilant Life Sciences

Jubilant Life Sciences has 3 listed competitors in our database, 3 of them funded. They include Akums, Nectar Lifesciences and Windlas.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Akums
akums.in2004Delhi, India$70M395
CDMO focusing on spectrum of dosage forms and therapeutic segments
Nectar Lifesciences
neclife.com1995Chandigarh, India$46.85M175
Cephalosporin APIs and generic formulations are manufactured.
Windlas
windlas.com2001Gurugram, India$12.96M1,264
Biopharma regulatory affairs, quality control, and strategy services are provided.
Premium access

Detailed competitors of Jubilant Life Sciences

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Jubilant Life Sciences

The website of Jubilant Life Sciences (jubl.com) receives about 48.5K visits a month.

  • Monthly visits
    48.5K

    ▼ 19.8% vs previous month

Similar websites

Websites whose visitors overlap most with Jubilant Life Sciences. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Granules India
granulesindia.com
100%
14.1K#1,691,049View details
Jubilant Pharmova
jubilantpharmova.com
84%
7K#3,116,802View details
Jubilant FoodWorks
jubilantfoodworks.com
51%
31.6K#964,839View details
Jubilant Biosys
jubilantbiosys.com
51%
12.2K#2,731,637View details
Jubiliant Industries
jubilantindustries.com
51%
1.9K#8,593,046View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 10 similar websites and full traffic analytics for Jubilant Life Sciences

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 10 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Jubilant Life Sciences (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Anthem Biosciences
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M2,062
Laurus Labs
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M548
Entero Healthcare
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M557
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Jubilant Life Sciences

JUBLPHARMA: Rs. 18.28 Crores NSE Block Trade; for ~ 200,560 Shares, at Rs. 911.60
Exchange Update • 29 days ago
Jubilant Pharmova: Board Agrees To Issue Up To ₹800 Crore In Non-Convertible Debentures Through Private Placement; Looking For Member Approval For Up To ₹2,500 Crore In Debt Securities Over The Next Year.
Exchange Update • 29 days ago
Jubilant Pharmova: Company Announces CAD 94.5 Million Investment to Increase Ruby-Fill® Production Capacity; Government of Canada to Provide CAD 23.8 Million in Support; Expansion Targets Growing Demand in Radiopharmaceuticals.
Exchange Update • 1 month ago
Jubilant Pharmova: Weighs Options To Raise Funds By Issuing Non-Convertible Debentures.
Exchange Update • 1 month ago
Jubilant Pharmova’s Spokane facility gets VAI classification from US FDA - The HinduBusinessLine
Thehindubusinessline • 1 month ago
Jubilant Pharmova's US CMO facility gets 'Voluntary Action Indicated' classification - CNBC TV18
CNBCTV18 • 2 months ago
Jubilant Pharmova Receives Tax Show Cause For 873.1 Million Rupees
Reuters • 2 months ago
Stocks to watch: ZEEL, Vodafone Idea, Jubilant Pharmova, Power Grid | Markets News - Business Standard
Business Standard • 2 months ago
Buzzing Stocks: Meesho shares slip on block deal; Apollo Tyres gains 2% after UBS upgrade to ‘buy’
Moneycontrol • 2 months ago
Volumes soar at Lenskart Solutions Ltd counter | Capital Market News - Business Standard
Business Standard • 2 months ago
Premium access

Complete news archive for Jubilant Life Sciences

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Jubilant Life Sciences

Jubilant Life Sciences was founded in 1978 and raised its 1st funding round 25 years after it was founded.

Jubilant Life Sciences is headquartered in Noida, India. It is registered at Noida, Uttar Pradesh, India.

Jubilant Life Sciences has 165 employees.

The primary company behind Jubilant Life Sciences, Jubilant Pharmova Limited, reported revenue of ₹8,346 Cr for FY 2026, up 14% year on year.

Founded in 1978, operations are conducted in the pharmaceutical and life sciences sectors from Noida, India. APIs, solid dosage formulations, radiopharmaceuticals, and allergy therapy products are manufactured and supplied, alongside contract services for sterile injectables and drug discovery. Advanced intermediates, fine ingredients, and nutritional products are also produced. Facilities are maintained in India and North America, with products distributed to over 100 countries across North America, Europe, India, and China.

Jubilant Life Sciences's top competitors include Akums, Nectar Lifesciences and Windlas.

Jubilant Life Sciences offers Pharmaceuticals, Drug Discovery Solutions, Proprietary Novel Drugs, and Specialty Chemicals.

Yes, Jubilant Life Sciences is publicly traded on NSE under the ticker symbol JUBLPHARMA.

Jubilant Life Sciences has made 5 acquisitions, including Bestcro, DRAXIS Health, and Hollister-Stier.

Jubilant Life Sciences has 1 investor. Key investors include General Atlantic.

Jubilant Life Sciences is associated with 4 legal entities: Jubilant Pharmova Limited, Jubilant Innovation (India) Limited, Vanthys Pharmaceutical Development Private Limited and others.

The legal entities of Jubilant Life Sciences currently have 21 directors, including Sankaraiah Rajagopal, Arun Kumar Sharma, Benny Thomas and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available